Silencing of p53 RNA through transarterial delivery ameliorates renal tubular injury and downregulates GSK-3β expression after ischemia-reperfusion injury

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 11, 2013, Pages

  Fujino, Takayuki ^a   Muhib, Sharifi ^a   Sato, Nobuyuki ^a   Hasebe, Naoyuki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Acute kidney injury; Ischemia reperfusion injury; p53; Transarterial delivery

Indexed keywords

BETA CATENIN; CREATININE; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; POLYMER; PROTEIN P53; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HENLE LOOP; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY MEDULLA; KIDNEY TUBULE CELL; KIDNEY TUBULE DAMAGE; MITOCHONDRION SWELLING; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RENAL ARTERY; REPERFUSION INJURY; STAINING; SYSTEMATIC REVIEW; UPREGULATION;

EID: 84888789896     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00279.2013     Document Type: Article

References (40)

1. Adams CL, Nelson WJ. Cytomechanics of cadherin-mediated cell-celladhesion. Curr Opin Cell Biol 10: 572-577, 1998.
2. Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382: 638-642, 1996.
3. Ben-Ze'ev A, Geiger B. Differential molecular interactions of betacatenin and plakoglobin in adhesion, signaling and cancer. Curr Opin Cell Biol 10: 629-639, 1998.
4. Bijur GN, Jope RS. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 276: 37436-37442, 2001.
5. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6: 1130-1146, 2011.
6. Ciaraldi TP, Oh DK, Christiansen L, Nikoulina SE, Kong AP, Baxi S, Mudaliar S, Henry RR. Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab 291: E891-E898, 2006.
7. Dihlmann S, Kloor M, Fallsehr C, von Knebel Doeberitz M. Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. Carcinogenesis 26: 1503-1512, 2005.
8. di Iasio MG, Addobbati R, Radillo O, Voltan R. Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. Invest New Drugs 30: 1761-1765, 2012.
9. Dimitrova YN, Li J, Lee YT, Rios-Esteves J, Friedman DB, Choi HJ, Weis WI, Wang CY, Chazin WJ. Ubiquitination of beta-catenin by Siah-1 and regulation by the exchange factor TBL1. J Biol Chem 285: 13507-13516, 2010.
10. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med 17: 1391-1401, 2011.
11. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 305: 626-629, 2004.
12. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 12: 613-626, 2012.
13. Heyman SN, Rosenberger C, Rosen S. Experimental ischemia-reperfusion: biases and myths-the proximal vs. distal hypoxic tubular injury debate revisited. Kidney Int 77: 9-16, 2010.
14. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 59: 3-10, 1996.
15. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549, 2004.
16. Kelly KJ, Plotkin Z, Vulgamott SL, Dagher PC. P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor. J Am Soc Nephrol 14: 128-138, 2003.
17. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC, Bonventre JV. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 97: 1056-1063, 1996.
18. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
19. Lee SJ, Chung YH, Joo KM, Lim HC, Jeon GS, Kim D, Lee WB, Kim YS, Cha CI. Age-related changes in glycogen synthase kinase 3 beta (GSK3 beta) immunoreactivity in the central nervous system of rats. Neurosci Lett 409: 134-139, 2006.
20. Longo KA, Kennell JA, Ochocinska MJ, Ross SE, Wright WS, Mac-Dougald OA. Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem 277: 38239-38244, 2002.
21. Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20: 27-39, 2001.
22. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534-2543, 2003.
23. Mohamed JS, Lopez MA, Boriek AM. Mechanical stretch up-regulates microRNA-26a and induces human airway smooth muscle hypertrophy by suppressing glycogen synthase kinase-3β. J Biol Chem 285: 29336-29347, 2010.
24. Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E, Brafman A, Faerman A, Atkinson SJ, Thompson JD, Kalinski H, Skaliter R, Erlich S, Feinstein E. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 20: 1754-1764, 2009.
25. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, Buchen C, Khan F, Mori K, Giglio J, Devarajan P, Barasch J. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 148: 810-819, 2008.
26. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49: 263-271, 2000.
27. Novak A, Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 56: 523-537, 1999.
28. Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, Meijer L, Nelson PJ. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int 73: 684-690, 2008.
29. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932, 1998.
30. Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM, Viltard M, Yu W, Forster CS, Gong G, Liu Y, Kulkarni R, Mori K, Kalandadze A, Ratner AJ, Devarajan P, Landry DW, D'Agati V, Lin CS, Barasch J. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 17: 216-222, 2011.
31. Proctor CJ, Gray DA. GSK3 and p53-is there a link in Alzheimer's disease? Mol Neurodegener 5: 7, 2010.
32. Rosenberger C, Rosen S, Shina A, Bernhardt W, Wiesener MS, Frei U, Eckardt KU, Heyman SN. Hypoxia-inducible factors and tubular cell survival in isolated perfused kidneys. Kidney Int 70: 60-70, 2006.
33. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of betacatenin by activated p53. Mol Cell Biol 21: 6768-6781, 2001.
34. Schwartz JH, Shih T, Menza SA, Lieberthal W. ATP depletion increases tyrosine phosphorylation of beta-catenin and plakoglobin in renal tubular cells. J Am Soc Nephrol 10: 2297-2305, 1999.
35. Sharpe C, Lawrence N, Martinez Arias A. Wnt signalling: a theme with nuclear variations. Bioessays 23: 311-318, 2001.
36. Srichai MB, Hao C, Davis L, Golovin A, Zhao M, Moeckel G, Dunn S, Bulus N, Harris RC, Zent R, Breyer MD. Apoptosis of the thick ascending limb results in acute kidney injury. J Am Soc Nephrol 19: 1538-1546, 2008.
37. Sugden PH, Fuller SJ, Weiss SC, Clerk A. Glycogen synthase kinase 3 (GSK-3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol 153: S137-S153, 2008.
38. Takahashi Y, Nishikawa M, Takakura Y. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv Drug Deliv Rev 61: 760-766, 2009.
39. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90: 377-379, 2002.
40. Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, Johnson GV, Jope RS. Direct, activating interaction between glycogen synthase kinase-3 beta and p53 after DNA damage. Proc Natl Acad Sci USA 99: 7951-7955, 2002.